 controlled trial aerosolized ribavirin infants mechanical ventilation severe respiratory syncytial virus infection BACKGROUND antiviral agent ribavirin course respiratory tract disease infants respiratory syncytial virus infection ribavirin infants severe respiratory syncytial virus disease mechanical ventilation METHODS double-blind placebo-controlled evaluation ribavirin mg milliliter aerosolized form infants mechanical ventilation respiratory failure documented respiratory syncytial virus infection RESULTS infants mean SD age months underlying diseases infection mean age months normal mean age month infants ribavirin mean duration mechanical ventilation days days placebo mean length supplemental oxygen use days days mean length hospital stay days treatment ribavirin placebo normal infants mean length hospital stay days ribavirin recipients days placebo CONCLUSIONS infants mechanical ventilation severe respiratory syncytial virus infection treatment aerosolized ribavirin duration mechanical ventilation oxygen treatment hospital stay